This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06987513 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Altimmune, Inc. |
| Enrollment | 100 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Alcohol Use Disorder (AUD) |
| Interventions | Pemvidutide; Placebo |
| Start | May 15, 2025 |
| Primary completion | Jul 30, 2026 |
| Study completion | Jul 30, 2026 |
| Results posted | Not yet |
| Registry last updated | Jul 31, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms:
* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from baseline in the average number of heavy drinking days per week | Baseline to Weeks 21-24 |
10 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.